



## 4th THORACIC CANCERS ACADEMY

## 19. - 20. January 2024

## Hilton Garden Inn Zagreb,Croatia

#### **Scientific Committee**

Mir Alireza Hoda (Vienna, Austria) Marko Jakopović (Zagreb, Croatia) Tanja Čufer (Ljubljana, Slovenia) Davorin Radosavljevic (Belgrade, Serbia) Tanya Zlatanova (Sofia, Bulgaria) Christoph Zielinski (Vienna, Austria) Christiane Thallinger (Vienna, Austria)



### SCIENTIFIC PROGRAMME

#### Friday, January 19, 2024

c	5	
ó	ľ	
į		
ł		
E	t	

## :10-11:50

## 12:20-13:1

# 14:30-15:

15:10-16:20

#### Welcome

Chair M. Jakopovic, Zagreb Chair C. Zielinski, Vienna

Welcome - M. Jakopovic, Zagreb and C. Zielinski, Vienna

Introduction to CECOG - C. Zielinski, CECOG

**News in Screening and Staging** 

Chair M. Samarzija, Zagreb Chair C. Zielinski, Vienna

Lung cancer screening in Croatia - first national screening in Europe - M. Samarzija, Zagreb

Screening in smokers and non-smokers - state of the art - A. Marusic, Zagreb

Panel Discussion and O&A

Coffee Break 11:50-12:20

#### Early stage NSCLC - current treatment paradigms

Chair T. Klikovits, Vienna

Chair J. But Hadzic, Ljubljana

Bronchoscopic tools for diagnosis and staging - state of art - S. Badovinac, Zagreb

Surgery for very early and early NSCLC - less is more? - T.Klikovits, Vienna

SBRT in inoperable and operable early NSCLC - J. But Hadzic, Ljubljana

Panel Discussion and O&A

Lunch Break 13:15-14:30

#### **SCLC and Thymic Malignancies**

Chair M. Jakopovic, Zagreb Chair C. Zielinski, Vienna

Systemic treatment of SCLC (including novel approaches) - J. Spasic, Belgrade

Thymic Malignancies: Current standards in treatment - M. Jakopovic, Zagreb

Panel Discussion and O&A

#### Systemic treatment NSCLC

Chair T. Cufer, Ljubljana

Chair D. Radosavljevic, Belgrade

Molecular characterization of NSCLC - I. Kern, Golnik

Perioperative systemic therapy for resectable NSCLC- T. Cufer, Ljubljana

Treatment of oncogene-addicted advanced NSCLC - T. Zlatanova, Sofia

Treatment of non-oncogene-addicted advanced NSCLC - B. Zaric, Novi Sad

Panel Discussion and Q&A

# 8:30-09:40

### SCIENTIFIC PROGRAMME

#### Friday, January 19, 2024

#### Palliative and supportive Care in metastatic lung cancer

Chair T.Kovacevic, Novi Sad Chair S. Plestina, Zagreb

Interventional options for palliative patients - A. Rozman, Golnik

Is Surgery indicated in a pallitiave or salsvage setting? - G. Madzarac, Zagreb

Palliative and supportive Care in metastatic lung cancer – an update – T.Kovacevic, Novi Sad

Panel Discussion and Q&A

Sponsored Session I (17:40-18:40) Details to be found on the last page

Networking Dinner 20:00 at "Vetro Bar & Bites"

#### Saturday, January 20, 2024

#### Pleural Mesothelioma - whats new?

Chair C. Aigner, Vienna Chair M. Jakopovic, Zagreb

Update on histology and molecular pathology in PM - L. Brcic, Graz

Is surgery still indicated in PM? - C. Aigner, Vienna

The current role of radiation in PM - J. But Hadzic, Ljubljana

Systemic options including IO in PM - M. Jakopovic

Panel Discussion and O&A

Break 09:40-09:50

Sponsored Session II (09:50-10:20) Details to be found on the last page

Coffee Break 10:20-10:45

Sponsored Session III (10:45-11:15) Details to be found on the last page

Break 11:15-11:20

#### Young Oncologists session - MTB discussion of real-world cases

T. Cufer, M. Jakopovic, J. But Hadzic, L. Brcic

Panel Discussion and Q&A

#### **Closing Session**

T. Cufer, Ljubljana

11:20 - 11:50

## SPONSORED PROGRAMME

#### Friday, January 19, 2024

#### Satellite Symposium: Transforming care in early-stage lung cancer

Welcome and Introduction - M. Jakopovic, Zagreb

Optimising resectable NSCLC outcomes in patients with actionable mutations - U. Janzic, Golnik

Optimising resectable NSCLC outcomes in patients without actionable mutations - M. Jakopovic, Zagreb

Role of surgery in early-stage NSCLC - M.A. Hoda, Vienna

Improving outcomes in unresectable, locally advanced NSCLC - B. Zaric, Novi Sad

Panel Discussion and O&A



#### Saturday, January 20, 2024

#### Satellite Symposium

Pembrolizumab in early and metastatic lung cancer treatment – regardless of PD-L1 expression – *M. Jakopovic, Zagreb* 



#### Satellite Symposium: Advances in Adjuvant Treatment of Patients With NSCLC

Introdution - M. Jakopovic, Zagreb

Adjuvant immunotherapy with Atezolizumab in early NSCLC - T. Zlatanova, Sofia

Adjuvant Therapy for ALK-positive NSCLC - T. Cufer, Ljubljana

Panel Discussion and O&A



#### **FINANCIAL SUPPORT AND SPONSORS**

We kindly thank the following sponsors for their support of the 4th CECOG Thoracic Cancer Academy:









**EXHIBITOR** 

**PFIZER** 

17:40-18:40

09:50-10:20